The importance of N6-methyladenosine modification in tumor immunity and immunotherapy

Ze Zhang1,2†, Furong Liu1,2†, Wei Chen1,2,*, Zhibin Liao1,2, Wanguang Zhang1,2, Bixiang Zhang1,2, Huifang Liang1,2, Liang Chu1,2* and Zhanguo Zhang1,2*

Abstract
As the most common and abundant RNA modification in eukaryotic cells, N6-methyladenosine (m6A) modification plays an important role in different stages of tumor. m6A can participate in the regulation of tumor immune escape, so as to enhance the monitoring of tumor by the immune system and reduce tumorgenesis. m6A can also affect the tumor progression by regulating the immune cell responses to tumor in tumor microenvironment. In addition, immunotherapy has become the most popular method for the treatment of cancer, in which targets such as immune checkpoints are also closely associated with m6A. This review discusses the roles of N6-methyladenosine modification in tumor immune regulation, their regulatory mechanism, and the prospect of immunotherapy.

Keywords: N6-methyladenosine, Tumor immunity, Immune escape, Immunotherapy
Introduction
According to the data, more than 160 different types of RNA chemical modifications have been identified in all living organisms so far [1], including N6-methyladenosine (m6A), N1-methyladenosine (m1A), 5-methylcytosine (m5C), N7-methylguanosine (m7G), RNA cap methylation and so on. Among these modifications, N6-methyladenosine (m6A) is the most common and abundant RNA modification in eukaryotic cells [2, 3]. As a form of epigenetic regulation, m6A is a dynamic and reversible process, which is modulated by various enzymes in the mammalian cells [4]. N6-methyladenosine is enriched near stop codon and 3' untranslated terminal region (UTR), and translated near 5' UTR in a cap-independent manner as a means of fulfilling its function [5–7]. The function and mechanism of m6A modification have been widely studied in recent years, which is involved in many aspects of RNA metabolism, including pre-mRNA splicing, nuclear export, 3'-end processing, translation regulation, mRNA decay and noncoding RNA (ncRNA) processing [8–10]. A large number of studies have shown that m6A plays an important role in almost all biological processes, especially in tumorigenesis [11]. Recent studies have revealed that m6A can affect tumor progression through the regulation of immunity, which has become a research hotspot. In this review, we mainly discuss the abundant regulatory role of m6A in tumor immunity and escape mechanism, as well as tumor immunotherapy.

m6A writers, erasers and readers
m6A is catalyzed by RNA methyltransferase complex, which is composed of several components and called “writers” [12]. Methyltransferase-like 3 (METTL3), the first characteristic component of RNA methyltransferase complex, is a S-adenosylmethionine (SAM)-binding subunit, which mainly acts as the catalytic core [13, 14]. Methyltransferase-like 14 (METTL14) is another active component of m6A methyltransferase complex, which mainly functions as a supporting structure [14]. METTL3 and METTL14 coexist in the nuclear spots at the ratio of 1:1 and form a stable complex [15]. WTAP (Wilms tumor-associated protein) is the third core component of m6A methyltransferase complex. The main function of WTAP is to act as a junction protein for the interaction between METTL3 and METTL14, but without catalytic activity [16]. WTAP can also interact with many other components.
proteins and long non-coding RNAs (lncRNAs), suggesting that WTAP may recruit other factors to the methyltransferase complex [4]. METTL16 is an independent methyltransferase, which can catalyze m6A of mRNAs, lncRNAs and U6 small nuclear RNA [17]. In addition, KIAA142929 [18], RNA binding motif protein 15 (RBM15) and its analogue RBM15B30 [19] are all part of the RNA methyltransferase complex, which jointly catalyze the methylation of RNA.

Fat mass and obesity-associated protein (FTO) was the first m6A demethylase to be discovered [20], and then α-ketoglutarate-dependent dioxygenase homolog 5 (ALKBH5), was soon excavated [21]. Both FTO and ALKBH5 belong to the family of α-ketoglutarate-dependent dioxygenases, which are ferrous iron and α-ketoglutarate (αKG) cofactors-dependent demethylases [21]. They are mainly located in the nucleus where m6A demethylation occurs. Although the contents of FTO and ALKBH5 are different in various tissues [22], they both regulate the level of m6A in cells by reversing m6A modification. ALKBH3 is also an m6A demethylase, but it is more likely to modify tRNA than mRNA or rRNA [23]. The revealing of m6A demethylase indicates that m6A methylation is a reversible process, which enlightens the exploration of function and mechanism in m6A modification.

The secondary or tertiary structure of m6A-modified RNA will be changed, while “readers” can decode the m6A RNA methylation information in the cell [24, 25]. The “Readers” consist of YTH domain-containing proteins (YTHDF1/2/3 and YTHDC1/2), heterogeneous nuclear ribonucleoproteins (including hnRNPC, hnRNPQ and hnRNP2B1) and insulin-like growth factor 2 mRNA-binding proteins (IGF2BP) [26, 27]. The function of YTHDF1 is to interact with translation initiation factors to facilitate the translation efficiency of RNA [28]. In contrast, YTHDF2 accelerated the decline of m6A modified transcripts by directly recruiting the CCR4-NOT complex [29, 30]. YTHDF3 synergistically promotes protein synthesis and antagonizes YTHDF2-mediated mRNA decline [31–33]. As the only nuclear m6A “reader” protein, YTHDC1, also called YT521-B, has many functions, including recruiting some splicing factors to regulate the splicing of mRNA [34], promoting the output of mature mRNA [35] and the decay of specific transcripts [36]. While YTHDC2 can regulate mRNA stabilization and translation [37–39]. The functional core of IGF2BP protein is the KH3-4 domain, which can recognize m6A modification to enhance the stability and translation of its target mRNA [40]. HnRNP2B1 regulates the alternative splicing of exons and interacts with Dgcr8, a pri-miRNA microprocessor complex module, to regulate the nuclear processing of pri-miRNA (Fig. 1) [41].

m6A in tumor immunity

Regulation of m6A on immune cells

Tumor-associated macrophages (TAMs) are important regulators of tumorigenesis, which can exist in tissues or originate from peripheral hosts such as bone marrow (BM) and spleen [42]. Although macrophages are generally considered to be key effector cells in the process of immune defense [43], a large number of studies have proved that TAMs have a clear role in supporting tumor progression in many aspects. The two well-characterized extreme phenotypes of macrophages are M1 macrophages, and M2 macrophages [44, 45]. M1 macrophages are involved in pathogen clearance during infection by activating the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase system and subsequently generating reactive oxygen species (ROS) [46, 47]. M2 macrophages have strong phagocytosis ability, promote tissue repair, scavenge debris and apoptotic cells, and possess pro-angiogenic and pro-fibrotic properties [43, 45, 48]. In general, M1 macrophages mediate tissue damage induced by reactive oxygen species, and are helpful in antimicrobial and antitumor activities [43, 49]; M2 macrophages are involved in Th2 cell involved immune response and inflammatory suppression, and promote tissue remodeling, angiogenesis, tumor formation and progression [46, 50]. Studies have shown that m6A can regulate the polarization of macrophages by different mechanisms (Fig. 2A). Liu et al. found that METTL3 was specifically upregulated following polarization of mouse M1 macrophage [51]. Signal transducer and activator of transcription 1 (STAT1), is a major transcription factor that controls the polarization of M1 macrophage [52]. As a methyltransferase, METTL3 enhances the stability of STAT1 mRNA by specifically increasing the m6A modification of STAT1 mRNA in murine bone marrow-derived macrophages, and upregulates the expression of STAT1 mRNA to facilitate M1 macrophage polarization. On the other hand, the activation of STAT1 also inhibited the transcription activity of STAT6 which is the key transcription factor of M2 macrophage polarization mediated by IL-4. As a result, up-regulation of METTL3 facilitates M1 macrophage polarization and meanwhile inhibits M2 macrophage polarization [51]. Hence, METTL3 is involved in regulating the balance polarization of M1 and M2 macrophages. Besides, as a demethylase, FTO can also regulate M1 and M2 macrophage activation [53]. After FTO was knocked down in mouse macrophages, STAT1 expression was down-regulated in M1-polarized macrophages, while STAT6 and PPAR-γ expression was decreased in M2-polarized macrophages. FTO knockdown accelerates the mRNA decay of STAT1 and PPAR-γ in macrophage activation [44, 54], and this
process is also related to the involvement of YTHDF2, which has an effect on the stability of the mRNA of STAT1 and PPAR-γ. Moreover, FTO knockdown inhibits the activity of NF-κB signaling pathway, a main activation pathway for M1, and the activation of which promotes the expression of inflammatory factors TNF-α and IL-12 [55]. Last but not least, FTO knockdown can inhibit the phosphorylation of NF-κB signaling pathway in the activation of M1 macrophages, resulting in the suppression of the activation process of M1 macrophages [53]. Similarly, RBM4 overexpression can decrease m6A modified STAT1 mRNA to inhibit glycolysis in RAW264.7 macrophages by interacting with YTHDF2, thereby suppressing IFN-γ-induced M1 macrophage polarization [56]. In brief, FTO knockdown and RBM4 overexpression both inhibited the polarization of M1 macrophages, which is not advantageous for immune control of tumors.

On the other hand, the study found that deletion of METTL14 in myeloid cells exasperates the macrophage response to acute bacterial infection in mice [57]. Deletion of METTL14 in myeloid cells decreases methylation of SOCS1 mRNA, which maintains negative feedback control of macrophages. This leads to excessive activation of TLR4/NF-κB signaling pathway and release of excessive pro-inflammatory factors to enhance the inflammatory response [57]. This shows that m6A can be involved in the regulation of macrophage activation to exert anti-inflammatory effects, again demonstrating the important role of m6A on macrophage polarization.

Dendritic cells (DCs)
DC cells are a kind of antigen presenting cells, which can absorb, process and transmit antigen information in the body, and induce T and B cells to produce immune responses [58, 59]. In a study, Wang et al. found that METTL3 promotes dendritic cell activation by utilizing DC maturation and a differentiation model, including bone marrow-derived immature dendritic cell, LPS-stimulated BMDC (mature DC), and regulatory DC [60]. METTL3 promotes DC maturation in a m6A dependent manner, during which m6A modification level is increased. When METTL3 in DC cells is knocked out, TLR4/ NF-κB signaling pathway is defective, and IL-6 and IL-12 mRNA levels are decreased. This phenomenon suggests that METTL3 may promote the expression of NF-κB signaling pathway during DC maturation and activation through TLR4/NF-κB signaling pathway. TIRAP, an adaptor in the TLR4/NF-κB signaling pathway [61], was subsequently found to be involved in the regulation of this process. In general, METTL3 can promote TIRAP,
CD80, CD40 mRNA translation in vivo and in vitro, which is positively correlated with YTHDF1. The up-regulation of TIRAP expression facilitated the enhancement of TLR4/NF-κB signaling pathway and the secretion of pro-inflammatory cytokines, while the up-regulation of CD40 and CD80 expression led to the increase of DC antigen presentation and T cell stimulation [60]. Therefore, in vitro and in vivo, METTL3 promotes T cell proliferation through its m6A catalytic activity, which is required for DC function.

In addition m6A modification of mRNA is closely related to the regulation of persistent neoantigen-specific immunity of DC cells through the m6A-binding protein YTHDF1 [62]. Tumor immune infiltrations in YTHDF1-deficient mice contained higher levels of CD8+ cytotoxic T cells and natural killer (NK) cells compared with wild-type mice, indicating that immune surveillance was enhanced in the absence of YTHDF1. So, the absence of YTHDF1 in classical dendritic cells enhanced the cross-presentation of tumor antigens and the cross-primers of CD8+ T cells in vivo without affecting DCs development or activation [62]. Mechanistically, lysosomal cathepsin, as the main target of YTHDF1 control, affects the cross-priming ability of DCs. Lysosomes contain many types of molecules, such as proteases and antimicrobial peptides, which can be involved in the degradation of permissible pathogens or play a key role in the presentation of MHC class II–restricted antigen presentation [63, 64]. YTHDF1 can identify transcripts that encode lysosomal proteases labeled by m6A, and binds to these transcripts, increasing the translation of lysosomal cathepsin in dendritic cells. Hence, inhibition of cathepsin significantly enhanced the cross-presentation of wild-type dendritic cells. Neoantigen recognition is sufficient to induce a persistent T cell response, which is necessary for complete tumor rejection. Therefore, modulation of YTHDF1 for durable neoantigen-specific immunity may provide new perspectives for enhanced immunotherapeutic response (Fig. 2B) [65].

**T cells**

T cells, as the main group of cellular immunity, play an important role in the killing of tumor cells. In the tumor microenvironment, CD8+ T subtypes in T cells can cause

---

**Fig. 2** Regulation of m6A on immune cells. A The modification of m6A can regulate the polarization of macrophages. B The modification of m6A can regulate antigen presentation of DCs and T cell stimulation. C The modification of m6A can regulate the homeostasis of T cells.
killing effect on tumor cells [65], and CD4+ T cells can regulate or assist other lymphocytes to function, while Treg cells can inhibit the activation and proliferation of CD4+ T cells and CD8+ T cells in immune system [66]. Each type of T cell performs its specific function and together build a stable immune system. However, mRNA methylation can control T cell homeostasis and differentiation (Fig. 2C) [67]. After METTL3 was knockout in naive T cells, METTL3-deficient naive T cells showed a decrease ratio in TH1 and TH17 cells, and an increase ratio in TH2 cells compared to wild-type naive T cells, which indicate that m6A modification plays an important role in the differentiation of CD4+ T cells. Furthermore, m6A controls the balance of two important signaling pathways that control T cell homeostasis, namely IL-7-mediated JAK-STAT signaling and TCR-mediated ERK/AKT signaling. As the main survival pathway of cells, JAK-STAT signaling can be activated by IL-7 and protect effector / memory T cells from apoptosis [68]. In particular, SOCS protein is a physiological inhibitor of JAK-STAT signaling pathway [69]. SOCS1 negatively regulates IL-7 signaling, while SOCS3 and CISH can inhibit STAT5 phosphorylation and T cell proliferation [69, 70]. SOCS1, SOCS3, and CISH showed higher expression levels in METTL3-deficient primitive T cells. The increased activity of the SOCS family inhibited IL-7-mediated STAT5 activation and T cell homeostasis proliferation and differentiation. Therefore, m6A regulates T cell homeostasis by inducing degradation of transcripts of SOCS family in vivo [67]. These findings suggest that m6A modification is critical to the regulation of T cell homeostasis and function.

Similarly, in colorectal cancer and melanoma, METTL3 or METTL14 improved tumor cells to anti-PD-1 therapy by regulating CD8+ T cells [71]. CD8+ T cells are essential for the control of tumor growth. They produce a variety of cytokines, mainly IFN-γ, TNF-α and other cytokines, which play an important role in anti-tumor immunity [72, 73]. Compared with control tumors, CD8+ T cells were significantly increased in METTL3 and METTL14 deficient tumors, and granzyme B expression was significantly enhanced in CD8+ T cells. METTL3 and METTL14 deficient cells contain more stable Stat1 and Irf1 mRNAs, and YTHDF2-mediated mRNAs stability also controls the expression of Stat1 and Irf1 genes. Besides, absence of METTL3 or METTL14 makes tumors increase sensitivity to IFN-γ. IFN-γ plays an important role in tumor immunologic surveillance [74]. In the early stage of immune response, IFN-γ mainly comes from NK cells, while in the adaptive stage of immune response, IFN-γ mainly comes from classical CD4+ T cells and CD8+ T cells [75, 76]. By inducing the production of CXCL9 and CXCL10, these chemokines promote the recruitment of CD8+ and CD4+ effector T cells and inhibit tumor growth [71]. In addition, CD8+ T cells were also regulated by YTHDF in melanoma. Ovalbumin-expressing (OVA) B16 melanoma cells were subcutaneously inoculated into wild-type and YTHDF1-deficient mice. Compared with wild-type mice, YTHDF1-deficient mice contained higher levels of CD8+ cytotoxic T cells, and natural killer (NK) cells in tumor immune infiltration. IFN-γ increased significantly in CD8+ cytotoxic T cells, and upregulated the expression of PD-L1 (ligand of PD1) [62]. Together, these results suggest a mechanism that m6A can modulate the efficacy of immunotherapy not only by regulating the number of CD8+ T cells and cytokine production in the tumor microenvironment, but also by achieving high antigen-specific CD8+ T cell antitumor response.

**Regulation of m6A on immune evasion**

Immune evasion of cancer is a major obstacle to the design of effective anticancer treatment strategies. Although researchers have made considerable progress in understanding how cancer evades destructive immunity, it is still a challenge to overcome the immune evasion in tumors [77]. Tumors remain latent in patients for years, when tumor cells can destroy the function of immune system in human body through immunosuppression or loss of target antigen expression, and finally eliminate the immune response [78]. It is at this stage that the tumor escapes from immune surveillance, leading to an apparent clinical cancer. There are many mechanisms that can lead to tumor immune evasion, such as the low immunogenicity of tumor and the decrease of tumor surface antigen expression, the weakening of immune system induced by tumors, the change of TME and so on [79]. More and more studies have shown that m6A plays an indispensable role in the regulation of immune evasion in various tumors and plays an indispensable role in this process (Fig. 3).

**Impact of antigen-presenting**

Defects in major histocompatibility complex (MHC) class I proteins of tumor cells affect antigen presentation and may lead to immune escape [80]. The loss of MHC I antigen presentation not only weakens the ability of natural immune response to control cancer [81], but also weakens the effect of immunotherapy that works by stimulating CD8+ T cells [82]. Autophagy can lead to sustained destruction of MHC-I proteins [83]. For example, in pancreatic ductal adenocarcinoma (PDAC), enhanced autophagy flux promotes tumor avoidance by down-regulating MHC-I molecules and by reducing immune
recognition induced by CD8$^+$ cytotoxic T lymphocytes (CTLs) [84]. Inhibition of autophagy is beneficial to the re-emergence of MHC-I on the surface of malignant cells, while the modification of m6A can regulate autophagy. FTO positively regulates autophagy in an enzyme activity-dependent manner. FTO extended the half-life of ULK1 transcription by reversing m6A mRNA modification of ULK1 transcription, and may affect the stability of ULK1 transcripts in a YTHDF2-dependent manner [85]. While in another study, it was demonstrated that the targets of YTHDF2 are ATG5 and ATG7. When FTO is silenced, YTHDF2 binds more ATG5 and ATG7 transcripts, leading to degradation of mRNA and reduced protein expression, thereby mitigating autophagy [86]. In addition, autophagy regulated by m6A modifications also plays a physiological role in cancer drug resistance. METTL3 can modify FOXO3 mRNA and increase its stability, a process that relies on the assistance of YTHDF1. As a result, deletion of METTL3 in HCC patients destabilizes FOXO3 mRNA and increases drug resistance in HCC by regulating autophagic flux [87]. On the other hand, loss of tumor-associated antigens is another factor that prevents immune recognition. Persistent T cell response is necessary for complete tumor rejection, but loss of tumor-associated antigen cannot induce a persistent T cell response [62]. In classical dendritic cells, YTHDF1 regulates persistent neoantigen-specific immunity. Deletion of YTHDF1 leads to cross-presentation of tumor antigens and in vivo CD8$^+$ T cell cross primers without affecting DCs development or activation [62]. This change undoubtedly enhances the immune system’s surveillance of cancer and it is more conducive to cancer detection and clearance.

**Impact of T cells**

T cells of the body’s immune system can be regulated by m6A and have a direct impact on the immune evasion of tumors. Especially the activity of various types of T cells, like CD8$^+$ T cells and Tregs, is a key factor in determining immune evasion [88]. In a recent study, the authors revealed that circIGF2BP3, a novel circRNA, can inhibit the infiltration of CD8$^+$ tumor infiltrating lymphocyte (TIL) and mediate immune evasion in non-small cell lung cancer (NSCLC) [89], which process is correlated with m6A modification. In NSCLC cells,METTL3-mediated m6A modification of circIGF2BP3 promotes circIGF2BP3 upregulation by promoting its back-splicing and circularization in a manner dependent on YTHDC1. CircIGF2BP3 stabilizes OTUB1 mRNA by competitively upregulating PKP3 expression, and then reduced PD-L1 ubiquitination and subsequent proteasome degradation, leading to CD8$^+$ T cell-mediated immune escape [89]. The eventual formation of immune evasion is closely related to the changes of T cells mediated by m6A in the tumor microenvironment. And this process was also involved and modulated by immune checkpoints, suggesting that immune checkpoints play a role in immune evasion at the same time. Similarly, in
colon cancer, regulatory T cells (Tregs), which inhibit immunity and promote tumorigenesis, were up-regulated and the infiltration of activated memory T cells CD4 (CD4+ T cells) was down-regulated in the group with high expression of the immune gene CD34/CD276. Regulatory T cell is a key factor in tumor immune escape. The hallmark of Treg cells is the transcription factor Foxp3, while Treg cells also express higher IL-2 receptors [90, 91]. IL-2 receptors can be regulated by the SOCS family and activate STAT5 [92]. When METTL3 in Treg cells is depleted, it will cause the increase of SOCS gene family mRNA, thus inhibiting the IL2-STAT5 signaling pathway, and finally maintain the Treg inhibitory function [93]. Exploring the mechanism of T cell-mediated immune evasion and discovering more about its relationship with m6A modifications will facilitate immunotherapy of tumors.

**Impact of immune checkpoints**

Immune checkpoints are a kind of immunosuppressive molecules, which are expressed on immune cells and can regulate the degree of immune activation [94]. They play an important role in preventing the occurrence of autoimmunity [95]. Immune checkpoint molecules keep the immune system within a normal range when it is activated, so that the immune system is not overactivated. Their abnormal expression and function are one of the important reasons for tumor immune escape. Programmed Cell Death Protein 1 (PD1) is a typical representative of immune checkpoint inhibitors. PD1 inhibits the function of T lymphocytes by binding to the ligand PDL1/PDL2, thereby inhibiting the autoimmune response [96, 97]. In melanoma, the modification of m6A in RNA can reduce the proliferation and viability of tumor cells, suggesting that m6A has anti-tumor effect in melanoma. FTO can reduce the enrichment of m6A in key melanoma promoting genes, including PD-1 (PDCD1), CXCR4 and SOX10, and maintain their mRNA stability. By enhancing the binding of PD1 to the ligand PDL1/PDL2, it reduced the immune regulatory response of melanoma, and then promoted the immune escape of tumor [98]. Furthermore, down-regulation of ALKBH5 was associated with positive Pembrolizumab or Nivolumab response to PD-1 blockade in melanoma patients, further demonstrating the role of m6A-modified and immune checkpoints in tumor immune evasion [99]. FTO was found to regulate the expression of PD-L1 in leukemia. Gene deletion of FTO significantly attenuates leukemia stem cell/initiation cell self-renewal and reprogramming immune response by inhibiting the expression of immune checkpoint genes (especially LILRB4) [100]. FTO suppression makes leukemia cells sensitive to T cell toxicity and overcomes hypomethylation induced immune evasion. This provides help for the treatment of leukemia. Similarly, osteopontin (OPN), expressed by tumor cells in colon cancer, is an immune checkpoint that is a ligand for CD44 on the surface of T cells, and by binding to CD44 can effectively suppress T cell activity, resulting in enhanced cancer immune tolerance [101]. Thus, when the suppressor of OPN, interferon regulatory factor 8 (IRF8) is reduced, OPN expression is significantly increased, leading to immune evasion of cancer.

**Immunotherapy**

In the previous part of the article, we have discussed various mechanisms of immune evasion and immune regulation in cancer. Currently, common cancer treatment methods in clinical practice mainly include chemotherapy and radiotherapy, immunotherapy, targeted therapy and surgical treatment [102]. Each of these methods has its own advantages and limitations, but one of the most promising treatments is immunotherapy. Cancer immunotherapy is a therapeutic method to control and remove tumors by restarting and maintaining the tumor-immune cycle and restoring the normal anti-tumor immune response of the body, including immune checkpoint blockade [103], cell therapy [104], therapeutic antibodies, cancer vaccine [105] and so on.

**Immune checkpoint blockade and m6A inhibitors**

Among many immunotherapy strategies, immune checkpoint blockade shows significant benefits. As a molecular target, immune checkpoint blockade enhances anti-tumor immunity by blocking inherent immune down-regulating factors, such as cytotoxic t-lymphocyte antigen 4 (CTLA-4) [106] and programmed cell death 1 (PD-1) or their ligands, programmed cell death ligand 1 (PD-L1) (Table 1) [107]. Programmed Cell Death Protein 1 (PD1) is a typical representative of immune checkpoint [108]. PD1 inhibits the function of T lymphocytes by binding to the ligand PD-L1/PD-L2, thereby inhibiting the autoimmune response [109]. A variety of tumors can be improved by inhibiting PD1/PD-L1, and PD-1 inhibitors Pembrolizumab and Nivolumab have been approved by the FDA for advanced melanoma and non-small cell lung cancer [110].

Interestingly, m6A modification is involved in the regulation of PD1, PD-L1 and affects the tumor response to anti-PD-1 therapy. For example, in melanoma, all of METTL3/14, ALKBH5 and FTO can modulate tumor response to anti-PD-1 therapy in mice. When Mettl3/14 was inhibited, the modification of mRNA in the tumor was reduced, leading to an increase in CD8+ T cells, and enhanced the response to anti-PD-1 therapy by a series of signaling pathways [71]. The low expression of demethylase ALKBH5 was associated with better survival in
patients with melanoma. ALKBH5 regulates the expression of Mct4/Scl16a3 and the content of lactic acid in tumor microenvironment, as well as the composition of Tregs and bone marrow-derived suppressor cells. When a specific ALKBH5 inhibitor ALK-04 was used, the expression of ALKBH5 was down-regulated and the effect of anti-PD-1 therapy was enhanced, indicating that ALKBH5 can be used as a potential therapeutic target for melanoma [99]. Similarly, inhibition of FTO can reduce tumor resistance to PD-1 therapy [98]. If inhibition of FTO is combined with anti-PD-1 blocking immunotherapy, the therapeutic effect is more pronounced. In addition, OVA-expressing B16 melanoma cell skins were inoculated into wild-type and YTHDF1−/− mice to construct models. PD-L1 checkpoint blockade was more effective in YTHDF1−/− mice than in wild-type mice. This was due to increased IFN-γ expression in CD8+ T cells of YTHDF1−/− mice, and IFN-γ signaling up-regulated PD-L1 expression [62]. This suggested that the combination of YTHDF1 inhibitor and checkpoint blockade may be a potential novel therapeutic strategy to improve the outcome of patients with low response to checkpoint blockade. Therefore, the rational use of m6A inhibitors has great potential and prospect for tumor regulation and treatment.

In fact, m6A inhibitors play a significant role in cancer treatment not only because of its anti-tumor immunity, but also because of its anti-tumor activity (Table 2). In leukemia, the use of CS1 and CS2 targeting FTO increases the sensitivity of AML cells to T cell toxicity

| Table 1 | Immune checkpoints, their ligands distribution and antibody |
|---|---|---|---|---|---|
| Immune checkpoint | Ligand | Distribution of ligand | Antibody | Antibody type | Cancer |
| CTLA-4 | CD80(B7-1) | APCs | Ipilimumab | Human IgG1 | Melanoma |
| PD-1 | PD-L1(B7-H1) | Hematopoietic cells | Pembrolizumab | Human IgG4 | Melanoma |
| | PD-L2(B7-DC) | Non-hematopoietic cells | Nivolumab | Human IgG4 | NSCLC |
| LAG-3 | MHC-II | APCs | Atezolizumab | Human IgG1 | NSCLC |
| | Galectin-3 | Tumor cells | GSK2831781 | Human IgG | Colon adenocarcinoma |
| | LSECtin | | | | Ovarian cancer |
| FGL-1 | | | | | |
| Tim3 | Galectin-9 | Hematopoietic cells | TSR-022 | Human IgG4 | Liver cancer |
| | Phosphatidyserine | Apoptotic cells | LY3321367 | Human IgG1 | Solid tumor |
| | CEACAM1 | Tumor cells | MBG453 | Human IgG4 | AML |
| | HMGB1 | | | | |
| | | | | | |
| TIGIT | CD155(PVR) | APCs, T cells | Tiragolumab | Human IgG1 | NSCLC |
| | CD112(PVR/L2) | Non-hematopoietic cells, Tumor cells | AB-154 | Human IgG1 | Solid tumor |
| | | | BMS-986,207 | Human IgG1 | |

| Table 2 | m6A inhibitors have different targets and mechanisms |
|---|---|---|---|---|
| Cancer/Disease | Drug | Target | Role | Mechanism |
| AML | STM2457 | METTL3 | Inhibitor | Weaken the proliferation of AML stem cells or leukemia |
| | SI1 | METTL14 | Regulator | Promote terminal myeloid differentiation of normal HSPCs/AML |
| | CS1/CS2 | FTO | Inhibitor | Inhibit AML cell survival |
| | R:2HG | FTO | Inhibitor | Increase the sensitivity of AML cells to T cell toxicity |
| | FB23-2 | FTO | Inhibitor | Inhibit the proliferation of AML and weaken aerobic glycolysis in sensitive leukemic cells |
| GBM | MA/MA2 | FTO | Inhibitor | Suppress proliferation and promote the differentiation of AML |
| Melanoma | ALK-04 | ALKBH5 | Inhibitor | Overcome tyrosine kinase inhibitor resistance |
| BC | MO-1-500 | FTO | Inhibitor | Suppress the growth and self-renewal of GSCs |
| LUAD | PKE | YTHDC2 | Regulator | Regulate the express of Mct4/Scl16a3 and lactic acid |
| | Sorafenib | | | Suppress survival of BC cells by decreasing IRX3 proteins |
| Testicular damage | MEHP | FTO | Inhibitor | Suppress SLC7A11-dependent antioxidant function |
| | | | | Regulate reduction of testosterone and increase of apoptosis |
and overcomes HMA-induced immune escape, thereby achieving therapeutic effects [100]. FB23-2 can also inhibit FTO to suppress proliferation and promote the differentiation of AML [111], and Rhein can inhibit FTO to overcome tyrosine kinase inhibitor [112]. Besides, FTO inhibitor MA/MA2 can suppress the growth and self-renewal of GSCs in GBM [113]. It can be seen that there are many kinds of FTO-targeting inhibitors and their application range is also very wide. In addition to FTO-targeting inhibitors, the latest research shows that a new small-molecule inhibitor of METTL3 against AML. STM2457 is a highly specific inhibitor of catalytic activity for METTL3, but has no significant inhibitory effect on other RNA methyltransferases. Pharmacological inhibition of METTL3 in vivo can weaken the proliferation of AML stem cells or leukemia, inhibit the expansion of AML, and lead to transplantation damage and prolongation of survival time of AML mice, but there was no such expression in normal non-leukemic hematopoietic cells [114]. While SPI1 can also inhibit AML cell survival by regulating METTL14 [115]. In addition to m6A inhibitors, some regulators targeting m6A can also exert anti-tumor effects. In colon cancer, the presence of LINRIS (Long Intergenic Noncoding RNA for IGFBP2 Stability) in large amounts maintains the stability of “reader” IGFBP2, because the autophagy-lysosome pathway is blocked [116]. When LINRIS is knocked down, the amount of IGFBP2 is reduced and downstream effect—the MYC-mediated glycolysis in CRC cancer cells decreases, leading to slower tumor growth. R-2HG, as a metabolite produced by mutant isocitrate dehydrogenases (IDHs), can inhibit FTO activity to increase the accumulation of m6A modified m6A in MYC transcripts of sensitive leukemia cells, resulting in decreased stability of MYC mRNA and downregulation of MYC signaling pathway [117]. This regulation helps to inhibit the proliferation of cancer. Interestingly, the latest research result shows that R-2HG also promotes its anti-tumor activity by participating in the glycolysis pathway. PFKP and LDHB play an important role in glycolysis and tumorigenesis of leukemia. They are regulated by the R-2HG/FTO axis in an m6A-dependent manner. R-2HG can block the post-transcriptional upregulation of PFKP and LDHB mediated by FTO/m6A, thus attenuating aerobic glycolysis in sensitive(IDH-wildtype) leukemic cells and inhibiting the occurrence of leukemia [118]. This conclusion also indicates the therapeutic potential of m6A targeting tumor transcriptome and metabolism.

In summary, the above findings provide us with a new idea that the development of specific inhibitors targeting m6A regulators contributes to anti-tumor therapy. On the one hand, studies have shown that most m6A regulators are aberrantly highly expressed in tumors, so targeted inhibition of these regulators can directly inhibit tumor cell activity and further improve treatment outcomes and patient prognosis; on the other hand, the regulation of m6A is closely related to the development and function of immune cells. Targeted modulation of m6A can enhance the function and infiltration of immune cells in the tumor microenvironment and enhance the tumor response to anti-PD-1 therapy through a number of signaling pathways. It can be seen that the use of specific inhibitors targeting m6A regulatory factors can combine anti-tumor activity and anti-tumor immunity to play a comprehensive therapeutic effect. Attempts to combine m6A inhibitors and immune checkpoint blockade may be a new breakthrough in tumor immunotherapy.

In addition to immunotherapy targeting PD-1, Cytotoxic T-lymphocyte antigen 4(CTLA-4) is also a common target for tumor immunotherapy. CTLA-4 is a transmembrane protein expressed on the surface of activated T cells. CTLA-4 has two ligands: B7-1(CD80) and B7-2(CD86). When it binds to ligands, it produces inhibitory signals of T cells and inhibits the initiation of T cell immune responses, resulting in a decrease in activated T cells and preventing the formation of memory T cells [119]. Blocking CTLA-4 can restore the activity of T cells and prolong the survival time of memory T cells. This allows the body to further strengthen the immune function of tumor cells, resulting in increased tumor control rate [120]. Therefore, CTLA-4 inhibitors also play an important role in tumor immunity, especially in melanoma. Currently, CTLA-4 inhibitor Ipilimumab has been approved by FDA for the adjuvant treatment of stage III melanoma and the treatment of advanced melanoma [121], and clinical studies of Ipilimumab and Telinomab in kidney cancer, prostate cancer and lung cancer have been widely carried out. As for other immune checkpoints, such as LMTK3, LAG-3/CD223, TIM3, are also related to the activity and function of T lymphocytes and can be used as targets for immunotherapy (Table 1). For example, LMTK3 is a client protein of heat shock protein 90 (HSP90). It plays a cancer-promoting role in breast cancer, and C28, a LMTK3 small-molecule inhibitor, can promote proteasome-mediated LMTK3 degradation. The inhibition of C28 reduced the proliferation of NCI-60 tumor cell line and increased the apoptosis of breast cancer cells [122]. LAG3(Lymphocyte Activation Gene3) is mainly expressed in activated T lymphocytes, B lymphocytes, NK cells and plasma cell-like dendritic cells, and negatively regulates T cell function. LAG-3 selectively upregulates the expression of CD4 on the surface of Treg, and inhibition or knockout of LAG-3 will relieve the inhibitory function of Treg on T cells [123]. It is worth noting that when the interaction between LAG3 and ligand FGL1 is blocked by monoclonal antibodies, the
Although the relationship between these immune checkpoints is desired effect [127]. If properly combined with cell therapy alone may not achieve the desired effect. When the immunogenicity of cancer is poor, the use of T cell immunotherapy to kill tumor cells. back to patients, so as to kill tumor cells directly or stimulate human immune response to kill tumor cells. Other IC8s combined with TIGIT blocking can enhance the anti-tumor immune response, such that blocking TIGIT and PD-1 together can enhance the proliferation of CD8\(^+\) T cells and protect memory T cells [126]. Although the relationship between these immune checkpoints and m6A has not been deeply studied, their potential impact on tumor immunotherapy cannot be ignored.

**Cell therapy and m6A**

American biologist George Daley once said: "If the 20th century is the era of drug therapy, then the 21st century will be the era of cell therapy." Cell therapy can separate immunoreactive cells from tumor patients, amplify and identify their functions in vitro, and then infuse them back to patients, so as to kill tumor cells directly or stimulate human immune response to kill tumor cells. When the immunogenicity of cancer is poor, the use of immune checkpoint therapy alone may not achieve the desired effect [127]. If properly combined with cell therapy, immunotherapy for these poorly immunogenic types of cancer will be possible and may enhance the response of tumors that are already responsive to immune checkpoint therapy [104]. ACT mainly includes TIL, LAK, CIK, DC, NK, TCR-T, CAR-T and so on. As the “star” of tumor immune cell therapy, CAR-T cell therapy has shown satisfying targeting, lethality and persistence in clinical trials [128], which provides a new solution for immune cell therapy and shows great development potential and application prospects. CAR-T is a specific cellular immunotherapy [129], which is different from non-specific cellular immunotherapy such as CIK, DC-CIK, NK and so on. CAR combines the antigen binding domain with the additional costimulatory domain from CD28, OX40 and CD137 receptors and the signal domain of the TCR chain, which makes T cells have the specificity of cytotoxicity and antibody recognition at the same time [130]. In the second part of the article, we introduced that MHC I protein deficiency in tumor cells can affect antigen presentation and may lead to immune escape. CAR recognition overcomes the limitation that TCR needs MHC expression and recognition, and shows the anti-tumor advantage of CAR T cells. CD19 is a kind of B cell antigen expressed on the surface of normal and malignant B cells. The second-generation CAR T cells target CD19 and encode a costimulatory domain, showing a lasting response and strong curative effect on B-cell malignant tumors [131, 132]. However, although CAR T cells provide new ideas for the treatment of hematological malignant tumors, there are still many difficulties in successfully applying these treatments to solid tumors. But as discussed above, m6A modification is closely related to the function of T cells. For example, METTL3 can regulate the dynamic balance and differentiation of T cells, and YTHDF1 can regulate the number of CD8\(^+\) T cells infiltrated in tumor microenvironment in mice. Therefore, we make a conjecture that attempting to regulate m6A modification in CAR T cells may be a satisfying strategy to enhance tumor immunotherapy. Maybe with the continuous development of cell engineering and gene editing, this idea is expected to be gradually improved and applied to many types of tumor therapy.

In addition to CAR-T cell therapy, adoptive immunotherapy based on NK cells is also an important part of cell therapy [133]. Song et al. found that in mice, down-regulation of METTL3 expression in NK cells leads to a decrease in SHP-2 activity, which contributes to a decrease in NK cell response to IL-15, thereby affecting the proliferation and differentiation of NK cells [134]. This finding reveals the regulation of m6A modification on NK cells and provides a potential approach to address the problem of reduced proliferation efficiency of NK cells in vitro, which slows down the progress of cell therapy.

**m6A and other targets**

In addition to immune checkpoints and cell therapy, some regulatory cells related to tumor immunity, or related products involved in tumor immune escape, can be used as targets to enhance the effect of tumor immunotherapy [77]. For example, Tregs in tumor microenvironment inhibits the immune response of the body to tumor, which is a factor hindering immunotherapy [66]. It can be regulated by m6A to change the response of tumor to immunotherapy. The knockout of ALKBH5 can reduce the infiltration of Tregs in melanoma and enhance the response to anti-PD-1 therapy [99]; MDSCs can induce Tregs production, thus promote tumor angiogenesis and metastasis, so it can also be a target for improving treatment [135]; the polarization of macrophages can affect tumor formation, so altering macrophage polarization in the tumor microenvironment through m6A modification can also provide help in treating cancer [51, 53]; Tumor autophagy leads to tumor immune escape. m6A can control autophagy to improve the continuous destruction of MHC-I protein and the occurrence of
tumor immune escape, and then enhance the immune response of tumor to the body. To sum up, m6A is widely involved in all kinds of tumor immune regulation, and has great work and potential in tumor immunotherapy.

Discussion and perspectives
In recent years, the roles of m6A modification in different diseases and its molecular mechanism has become a research hotspot. m6A plays a dual role in cancer, like a double-edged sword. On the one hand, m6A can regulate the expression of oncogenes or tumor suppressor genes, thus affecting the progression of cancer; on the other hand, regulating the level of m6A and the expression and activity of m6A enzyme can affect the roles of m6A in cancer. In this review, we discuss the immunomodulatory effect of m6A on tumor from three stages: “tumor growth”-immune escape, “tumor control”- immune surveillance and “tumor elimination”-immunotherapy. In terms of immune evasion, we summarized that m6A can enhance the effect of antigen presentation, and can also modulate the immune activity of effector T cells after antigen presentation, thereby managing cancer evasion. When cancer destabilizes the body's immune system, m6A can modulate various immune cells in the tumor microenvironment to kill the cancer. By mediating macrophage polarization, DC maturation and T cell homeostasis and differentiation, m6A can exert effective control over tumor growth. Most importantly, m6A provides a new direction for the treatment of tumors. The levels of m6A affect the tumor response to immune checkpoint blockade therapy. Therefore, the combined use of m6A inhibitors and immune checkpoint blockade can be more favorable to patient treatment and prognosis. In fact, m6A modification can also improve the drug resistance of cancer cells and make other anti-cancer drugs work better, but this mechanism we do not detail here [136]. In conclusion, an in-depth understanding of the mechanism of m6A in immune regulation will help to develop new and effective treatment strategies, which can be used in the clinical treatment and prognosis of cancer patients.

Acknowledgements
Not applicable.

Author contributions
ZZ wrote the main manuscript text. ZF, FRL and WC prepared figures and tables. ZBL, HFL, WGW, BKZ, LC and ZGZ reviewed and edited the manuscript. ZGZ provided financial and administrative support. All authors read and approved the final manuscript.

Funding
This study was funded by National Natural Science Foundation of China (81502530, 82172976, 82103597).

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors have declared that no competing interest exists.

Received: 11 March 2022  Accepted: 16 April 2022
Published online: 19 May 2022

References
1. Boccaletto P, Machnicka MA, Purta E, Piatkowski P, Baginski B, Wierck K, de Crey-Lagard V, Ross R, Limbach PA, Kotter A, et al. MODOM-ICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res. 2018;46:D303–7.
2. Yue Y, Liu J, He C. RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation. Genes Dev. 2015; 29:1343–1355.
3. Jia G, Fu Y. Reversible RNA adenosine methylation in biological regulation. Trends Genet. 2013; 29:108–115.
4. Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. Biomed Pharmacother. 2019; 112:108613.
5. Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K, Jacob-Hirsch J, Amarglio N, Kupiec M et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012; 485:201–206.
6. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3'UTRs and near stop codons. Cell. 2012, 149:1635–1646.
7. Ke S, Allemu EA, Mertens C, Gantman EC, Fuk JJ, Mele A, Hanpal B, Zucker-Scharff F, Moore MJ, Park CY et al. A majority of m6A residues are in the last exons, allowing for the potential 3' UTR regulation. Genes Dev. 2015; 29:2037–2053.
8. Gilbert WV, Bell TA, Schaeining C. Messenger RNA modifications: Form, distribution, and function. Science. 2016, 352:1408–1412.
9. Lipshitz HD, Claycomb JM, Smibert CA. Post-transcriptional regulation of gene expression. Methods. 2017; 1261:1–2.
10. Roignant JY, Soller M, m6A in mRNA: an ancient mechanism for fine-tuning gene expression. Trends Genet. 2017; 33:380–390.
11. Pan Y, Ma P, Liu Y, Li W, Shu Y. Multiple functions of m6A RNA methylation in cancer. J Hematol Oncol. 2018; 11:48.
12. Bokar JA, MOER-S, Ludwiczak R, Narayann P, Rottman F. Characterization and partial purification of mRNA NG-Adenosine methyltransferase from HeLa Cell Nucle. J Biol Chem. 1994; 269:17697–17704.
13. Bokar JA, Shambaugh ME, Polayes D, Matera AG, Rottman FM. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. RNA. 1997;3:1233–1247.
14. Wang X, Feng J, Xue Y, Guan Z, Zhang D, Liu Z, Gong Z, Wang Q, Huang J, Tang C et al. Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex. Nature. 2016; 534:575–578.

15. Wang P, Doxtader KA, Nam T. Structural basis for cooperative function of METTL5 and METTL14 methyltransferases. Mol Cell. 2016; 63:306–317.

16. Liu J, Yue Y, Han D, Wang X, Fu Y, Zheng L, Jia G, Yu M, Lu Z, Deng X et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014; 10:93–95.

17. Pendleton KE, Chen B, Liu K, Hunter OV, Xie Y, Tu BP, Conrad NK. The U6 snRNA m(6)A methyltransferase METTL16 regulates SAM synthetase intron retention. Cell. 2017; 169:824–835.

18. Schwartz S, Mumbach MR, Iovanovic M, Wang T, Maciag K, Bushkin GG, Mertins P, Ter-Ovanesyan D, Habib N, Caciarelli D et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5’ sites. Cell Rep. 2014; 8:284–296.

19. Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Gutmann M, Jaffrey SR. m(6)A RNA methylation promotes MST-mediated transcriptional repression. Nature. 2016; 537:369–373.

20. Jia GF, Fu Y, Zhao X, Dai Q, Zheng GQ, Yang Y, Yi CQ, Lindahl T, Pan T, Yang YG et al. N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011; 7:885–7.

21. Zhou Z, Lv J, Yu H, Han J, Yang X, Feng D, Wu Q, Yuan B, Lu Q, Yang Y et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014; 10:93–95.

22. Lee M, Kim B, Kim VN. Emerging roles of RNA modification: m(6)A and U-tail. Cell. 2014; 158:980–987.

23. Ueda Y, Oshio I, Fusasue Y, Kite J, Kawaguchi M, Jingushi K, Hase H, Harada K, Hirata K, Tsuchioka K. AlkB homolog 3-mediated mRNA demethylation promotes protein synthesis in cancer cells. Sci Rep. 2017; 7:42271.

24. Liu C, Yang Z, Li R, Wu Y, Chi M, Gao S, Sun X, Meng X, Wang B. Potential roles of N6-methyladenosine (m6A) in immune cells. J Transl Med. 2021; 19:251.

25. Dai D, Wang H, Zhu L, Jin H, Wang X. N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis. 2018; 9:124.

26. Zhou Z, Li Y, Hu H, Han J, Yang X, Feng D, Wu Q, Yuan B, Lu Q, Yang H. Mechanism of RNA modification N6-methyladenosine in human cancer. Mol Cancer. 2020; 19:104.

27. Yi YC, Chen XY, Zhang J, Zhu JS. Novel insights into the interplay between m6A modification and noncoding RNAs in cancer. Mol Cancer. 2020; 19:121.

28. Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, Wang X, Chen K, Hu H, He C. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell. 2015; 161:1388–1399.

29. Huang T, Liu Z, Zheng Y, Feng T, Gao Q, Zeng W. YTHDF2 promotes spermiogenic adhesion through modulating MWWPs decay via m(6)A/mRNA pathway. Cell Death Dis. 2018; 9:124.

30. Zhou Z, Li Y, Hu H, Han J, Yang X, Feng D, Wu Q, Yuan B, Lu Q, Yang H. Mechanism of RNA modification N6-methyladenosine in human cancer. Mol Cancer. 2020; 19:104.

31. Yi YC, Chen XY, Zhang J, Zhu JS. Novel insights into the interplay between m6A modification and noncoding RNAs in cancer. Mol Cancer. 2020; 19:121.

32. Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, Wang X, Chen K, Hu H, He C. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell. 2015; 161:1388–1399.

33. Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, Liu C, He C. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res. 2017; 27:444–447.

34. Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, Liu C, He C. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res. 2017; 27:444–447.

35. Xiao W, Adhikari S, Dahal U, Chen YS, Hao YJ, Sun BF, Sun HY, Li A, Ping XL, Lai WY et al. Nuclear m6A reader YTHDC1 regulates mRNA splicing. Mol Cell. 2016; 61:507–519.

36. Roundtree IA, Luo GZ, Zhang Z, Wang X, Zhou T, Cui Y et al. YTHDC1 mediates nuclear export of N(6)-methyladenosine methylated mRNAs. Elife. 2016; e13131.

37. Shima H, Matsumoto M, Ishigami Y, Ebna M, Muno A, Sato Y, Kumagai S, Ochiai K, Suzuki T, Igashiri K. S-Adenosylmethionine Synthetase is regulated by selective N(6)-adenosine methylation and mRNA degradation involving METTL16 and YTHDC1. Cell Rep. 2017; 21:3354–3363.
59. Chen S, Fang L, Guo W, Zhou Y, Yu G, Li W, Dong K, Liu J, Luo Y, Wang B et al. Control of Treg cell homeostasis and immune equilibrium by Lkb1 in dendritic cells. Nat Commun. 2018; 9:5298.

60. Wang H, Hu X, Huang M, Liu J, Gu Y, Ma L, Zhou Q, Cao M. Mettl3-mediated m(6)A methylation promotes dendritic cell differentiation. Nat Commun. 2019; 10:18988.

61. Hong T, Barton GM, Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol. 2001; 2:835–841.

62. Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, Huang X, Liu Y, Wang J, Dougherty U et al. Anti-tumour immunity controlled through m(6)A mRNA and YTHDF1 in dendritic cells. Nature. 2019; 566:270–274.

63. Lennon-Dumenil AM, Bakker AH, Maehr R, Fiebiger E, Overkleeft HS, Dougherty U et al. m(6)A RNA modification controls autophagy through upregulating ULK1 protein abundance. Cell Res. 2018; 28:953–957.

64. Wang X, Wu R, Liu Y, Zhao Y, Bi Z, Yao Y, Liu Q, Shi H, Wang F, Wang Y. m(6)A mRNA methylation controls autophagy and adipogenesis by targeting Atg5 and Atg7. Autophagy. 2020; 16:1221–1235.

65. Lin Z, Niu Y, Wan A, Chen D, Li H, Sun L, Zhan S, Chen L, Cheng C et al. RNA m(6)A modification controls sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J. 2020; 39:e103181.

66. Zhou J, Ding T, Pan W, Zhu YL, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 2009; 125:1649–1654.

67. Lin Z, Wu T, She Y, Wu K, Gu S, Li L, Dong C, Chen C, Zhou Y. N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer. Mol Cancer. 2021;10:1105.

68. Chetoui N, Boisvert M, Gendron S, Aoudjit F. Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway. Immunology. 2010; 130:418–426.

69. Palmer DC, Restifo NP. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol. 2009; 30:592–602.

70. Fu C, Jiang A. Dendritic cells and CD8 T cell immunity in tumor microenvironment. Front Immunol. 2018; 9:3059.

71. Sutherland A, Lawton SW, Murrin D, Horne R, Allan CL et al. Analysis of protease activity in live antigen-presenting cells shows regulation of the phagosome proteolytic contents during dendritic cell activation. J Exp Med. 2002; 196:529–540.

72. Guermonprez P, Vallaudeau I, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002; 20:621–667.

73. Malik AB, Blumberg RS, Kielian T, Kodys K, Kalogerou A. Interferon-gamma reduces tumor progression and regression: a review. Biomark Res. 2020; 8:49.

74. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoeediting. Annu Rev Immunol. 2002; 20:621–667.

75. Wang J, Ding T, Pan W, Zhu YL, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 2009; 125:1649–1654.

76. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and regulatory T cells. Nat Rev Immunol. 2002; 2:835–841.

77. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting. Annu Rev Immunol. 2009; 27:337–376.

78. Klement JD, Paschall AV, Redd PS, Ibrahim ML, Lu C, Yang D, Celis E, Offringa R. Strategies for immunotherapy of cancer. Adv Immunol. 2021; 12:6363568.

79. Yamamoto K, Venada A, Yano J, Bancur DE, Kukuchi M, Gupta S, Sohn ASW, Mukhopadhyay S, Lin EY, Parker SJ et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020; 581:100–105.

80. Kroemer G, Zitvogel L. Seeking cellular fitness and immune evasion: autophagy in pancreatic carcinoma. Cancer Cell. 2020; 37:759–760.

81. Zhou J, Ding T, Pan W, Zhu YL, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 2009; 125:1649–1654.
103. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018; 378:158–168.

104. Met O, Jensen KM, Chamberlain CA, Donia M, Svane IM. Principles of adoptive T cell therapy in cancer. Semin Immunopathol. 2019; 41:49–58.

105. Vermaelen K. Vaccine strategies to improve anti-cancer cellular immune responses. Front Immunol. 2019; 10:108.

106. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007; 12:864–872.

107. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012; 24:207–212.

108. He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020; 30:660–669.

109. Han Y, Liu D, Li P. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020; 10:727–742.

110. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015; 4:560–575.

111. Huang Y, Su R, Sheng Y, Dong L, Dong Z, Xu H, Ni T, Zhang ZS, Zhang T, Li C et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell. 2019; 35:677–691 e610.

112. Chen B, Ye F, Yu L, Jia G, Huang X, Peng S, Chen K, Wang M, Gong S et al. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. J Am Chem Soc. 2012; 134:17963–17971.

113. Cui Q, Shi H, Ye P, Li L, Ou Q, Sun G, Sun G, Lu Z, Huang Y, Yang CG et al. m(6)A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Rep. 2017; 18:2622–2634.

114. Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, Pilka ES, Aspris D, Leggate D, Hendrick AG et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukemia. Nature. 2021; 593:597–601.

115. Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbe J, Shen C, Hu C et al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m(6)A modification. Cell Stem Cell. 2018; 22:191–205 e199.

116. Wang Y, Lu JH, Wu QN, Jin Y, Wang DS, Chen YX, Liu J, Luo XJ, Meng Q, Pu HY et al. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Mol Cancer. 2019; 18:1717–25.

117. Su R, Dong L, Li C, Nachergeae S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C et al. R-2HG exhibits anti-tumor activity by targeting FTO/m(6)A/MYC/PFKP/LDHB axis. Mol Cell. 2021; 81:922–939 e929.

118. Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018; 131:58–67.

119. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206:1717–25.

120. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Curr Clin Cancer Res. 2011; 17:6958–6962.

121. Dittroua A, Cilibraia C, Simidgala N, Papakyriakou A, Milton-Harris L, Vella V et al. The structure-function relationship of oncogenic LMTK3. Sci Adv. 2020;6(6):eabc3099.

122. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI et al. Role of LAG-3 in regulatory T cells. Immunity. 2004; 21:503–513.

123. Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. Semin Immunol. 2019; 42:101305.

124. Meyers JH, Sabatos CA, Chakravarti S, Kuchroo VK. The TIM gene family regulates autoimmunity and allergic diseases. Trends Mol Med. 2005; 11:362–369.

125. Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8(2):e000957.